跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PI3K-delta inhibitors (cancer)
首页
药物
PI3K-delta inhibitors (cancer)
PI3K-delta inhibitors (cancer)
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
PI3K-delta inhibitors for treatment of pancreatic cancer
申请人: EONKETULA INC
优先权: 2021
CN
Inhibitors of PI3K p-delta 110 for use in delivery of viruses in the treatment of cancer
申请人: UNIV LONDON QUEEN MARY
优先权: 2016
CN
US
2 件公开
Purine inhibitors of human phosphatidylinositol 3-kinase delta
申请人: MERCK SHARP & DOHME
优先权: 2015
US
Purine inhibitors of human phosphatidylinositol 3-kinase delta
申请人: MERCK SHARP & DOHME
优先权: 2017
US
Purine inhibitors of human phosphatidylinositol 3-kinase delta
申请人: MERCK SHARP & DOHME
优先权: 2017
US
Dual selective PI3K delta and gamma inhibitors and/or salt-inducible kinase 3 inhibitors for treatment of solid tumors
申请人: RHIZEN PHARMACEUTICALS SA
优先权: 2022
CN
PI3K (delta) SELECTIVE INHIBITORS
申请人: LIANG CONGXIN
优先权: 2010
CN
US
4 件公开
药物
反馈